Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Travere Therapeutics Inc shares valued at $11,940 were sold by Inrig Jula on Jul 01 ’25. At $14.65 per share, Inrig Jula sold 815 shares. The insider’s holdings dropped to 88,787 shares worth approximately $1.32 million following the completion of this transaction.
Also, Cline Christopher R. sold 1,784 shares, netting a total of over 37,553 in proceeds. Following the sale of shares at $21.05 each, the insider now holds 93,126 shares.
Before that, Dube Eric M had sold 18,924 shares from its account. In a trade valued at $398,350, the CHIEF EXECUTIVE OFFICER traded Travere Therapeutics Inc shares for $21.05 each. Upon closing the transaction, the insider’s holdings decreased to 18,924 shares, worth approximately $6.22 million.
Analysts at Citigroup resumed the stock at ‘”a Buy”‘ outlook in a report released in mid June. As of January 10, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for TVTX. Earlier on October 21, 2024, Wells Fargo upgraded its rating. Their new recommendation was “an Overweight” for TVTX stock which previously was a “an Equal weight”.
Analyzing TVTX Stock Performance
On last trading session,, Travere Therapeutics Inc [NASDAQ: TVTX] rose 0.88% to $14.84. The stock’s lowest price that day was $14.43, but it reached a high of $15.0 in the same session. During the last five days, there has been a drop of approximately -0.70%. Over the course of the year, Travere Therapeutics Inc shares have jumped approximately 80.54%. Shares of the company reached a 52-week high of $25.29 on 02/11/25 and a 52-week low of $12.91 on 04/09/25.
Support And Resistance Levels for Travere Therapeutics Inc (TVTX)
According to the 24-hour chart, there is a support level at 14.51, which, if violated, would cause prices to drop to 14.17. In the upper region, resistance lies at 15.09. The next price resistance is at 15.33. RSI (Relative Strength Index) is 44.76 on the 14-day chart, showing neutral technical sentiment.
Is Travere Therapeutics Inc subject to short interest?
Stocks of Travere Therapeutics Inc saw a sharp steep in short interest on 2025-06-13 dropping by -0.11 million shares to 10.33 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 10.43 million shares. A decline of -1.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.57 of the overall float, the days-to-cover ratio (short ratio) decline to 5.57.
Which companies own the most shares of Travere Therapeutics Inc (TVTX)?
In terms of Travere Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 21.5 in the next 12 months, up nearly 46.16% from the previous closing price of $14.71. Analysts anticipate Travere Therapeutics Inc stock to reach 33 by 2025, with the lowest price target being 12. In spite of this, 8 analysts ranked Travere Therapeutics Inc stock as Buy at the end of 2025.
